00
009290.KO Kwangdong Phar
- Market cap
- KRW 324B
- P/E
- 14.4x
- P/B
- 0.49x
- ROE
- 2.2%
- Dividend yield
- 1.21%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 009290.KO undervalued?
Graham number009290.KO trades 44.2% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kwangdong Phar fundamental analysis
No fundamental analysis for Kwangdong Phar yet.
Kwangdong Phar stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kwangdong Phar
Kwang Dong Pharmaceutical Co., Ltd. operates as a human healthcare provider in South Korea. It develops and sells OTC drugs in the areas of ophthalmic, mineral preparations, nutritious tonics, antipyretic, analgesic, anti inflammatory agents, circulating system, and vitamins; and ETC drugs in the areas of anti-malignant-tumor agent, obesity drug, appetite suppressant, antipyretic, analgesic, anti-inflammatory agents, neuropsychiatric solvent, digestive organ agent, antibioti…
Full company profileKwangdong Phar financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kwangdong Phar annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.06T | 1.14T | 1.18T | 1.24T | 1.24T | 1.34T | 1.43T | 1.51T | 1.64T | 1.66T | 1.70T |
| Gross Profit | 248B | 247B | 242B | 259B | 258B | 274B | 282B | 300B | 299B | 301B | 303B |
| Operating Income | 44.4B | 35.7B | 33.9B | 41.8B | 46.6B | 44.9B | 38.2B | 42.1B | 30.1B | 31.0B | 20.7B |
| EBITDA | - | 51.2B | 51.6B | 58.7B | 85.2B | 51.0B | 54.0B | 68.8B | 82.1B | 60.0B | 56.6B |
| Net Income | 28.1B | 23.2B | 22.3B | 23.1B | 45.4B | 24.0B | 24.2B | 37.0B | 40.5B | 21.0B | 14.2B |
| EPS | - | 572 | 556 | 583 | 1,104 | 585 | 588 | 922 | 1,029 | 422 | 286 |
| Balance Sheet | |||||||||||
| Total Assets | 680B | 723B | 732B | 793B | 831B | 884B | 932B | 1.08T | 1.17T | 1.32T | 1.31T |
| Total Liabilities | 280B | 306B | 301B | 345B | 328B | 357B | 385B | 490B | 552B | 609B | 605B |
| Shareholders' Equity | 373B | 392B | 405B | 423B | 478B | 499B | 517B | 545B | 579B | 656B | 639B |
| Cash & Short-term Investments | 42.7B | 47.6B | 67.5B | 76.3B | 54.9B | 84.0B | 104B | 77.3B | 116B | 141B | 87.4B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 28.8B | 23.5B | 53.1B | 29.3B | 22.8B | 54.9B | 62.8B | -11.7B | -12.2B | 82.3B | -47.0B |
| Capital Expenditure | 18.1B | 14.1B | 18.8B | 12.6B | 5.26B | 23.8B | 25.4B | 35.2B | 77.8B | 26.4B | 10.4B |
| Free Cash Flow | - | 5.37B | 34.0B | 16.6B | 17.5B | 30.5B | 36.8B | -46.9B | -89.9B | 56.0B | -57.4B |
| Ratios | |||||||||||
| ROE | 7.5% | 5.9% | 5.5% | 5.5% | 9.5% | 4.8% | 4.7% | 6.8% | 7.0% | 3.2% | 2.2% |
| ROA | 4.1% | 3.2% | 3.1% | 2.9% | 5.5% | 2.7% | 2.6% | 3.4% | 3.5% | 1.6% | 1.1% |
| Net Profit Margin | 2.7% | 2.0% | 1.9% | 1.9% | 3.6% | 1.8% | 1.7% | 2.4% | 2.5% | 1.3% | 0.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Kwangdong Phar dividends
- Dividend yield
- 1.21%
- Forward dividend
- 100.00 KRW
- Payout ratio
- 18.7%
- Ex-dividend date
- Mar 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 3.93B | 79 | 18.7% |
| 2024 | KRW 4.01B | 102 | 9.9% |
| 2023 | KRW 4.11B | 102 | 11.1% |
| 2022 | KRW 4.11B | 100 | 17.0% |
| 2021 | KRW 4.11B | 100 | 17.1% |
| 2020 | KRW 3.17B | 77 | 7.0% |
| 2019 | KRW 3.21B | 81 | 13.9% |
| 2018 | KRW 3.25B | 81 | 14.5% |
| 2017 | KRW 3.25B | 80 | 14.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 884:825 on Jul 1, 1999.
Who owns Kwangdong Phar
- Insiders 19.61%
- Institutions 14.53%
- Public & others 65.86%
- Shares outstanding 49.7M
- Free float 42.5M
Kwangdong Phar company profile
- Company name
- Kwangdong Phar
- Ticker
- 009290.KO
- ISIN
- KR7009290008
- Exchange
- Korea Stock Exchange
- Sector
- Consumer Defensive
- Industry
- Pharmaceuticals
- Employees
- 1,001
- Fiscal year end
- December
- Address
- Gasan Building, Seoul, South Korea
- Phone
- 82 2 6006 7777
- Website
- ekdp.com
About Kwangdong Phar
Kwang Dong Pharmaceutical Co., Ltd. operates as a human healthcare provider in South Korea. It develops and sells OTC drugs in the areas of ophthalmic, mineral preparations, nutritious tonics, antipyretic, analgesic, anti inflammatory agents, circulating system, and vitamins; and ETC drugs in the areas of anti-malignant-tumor agent, obesity drug, appetite suppressant, antipyretic, analgesic, anti-inflammatory agents, neuropsychiatric solvent, digestive organ agent, antibiotic, and vitamins. The company also offers supplements for low content vitamin, mineral or vital energy substance and quasi drugs. In addition, it provides blackberry, ginger lonicerae flos, vita gold, and red ginseng gold drinks, as well as offers water, mixed drinks, tea drinks, and other drinks; and traditional health foods. The company offers its products through operation of TV, radio, and print advertising. Kwang Dong Pharmaceutical Co., Ltd. was founded in 1963 and is based in Seoul, South Korea.
Kwangdong Phar management
4- Mr. Hyun-Sik KimPresident and Director · born 1954
- Mr. Kwa-Kyun MoPresident and Director · born 1965
- Mr. Sung-Won ChoiChairman & CEO · born 1969
- Mr. Ju-Hoon AhnSenior Managing Director and Director · born 1966